score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical	Preclinical		Copy Number	MIR17HG	Amplification				0.0	0.0		Putatively Actionable	Neoadjuvant chemotherapy + surgery	Combination therapy	Amplification of the 13q31-34 region, which contains MIR17HG, was associated with increased sensitivity to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.	Molinari C, Salvi S, Foca F, et al. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther. 2016;9:2735-42.	https://doi.org/10.2147/OTT.S105760	Investigate Actionability - Low	Neoadjuvant chemotherapy + surgery	Combination therapy	Deletion of the 13q31-34 region, which contains MIR17HG, was associated with resistance to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.	Molinari C, Salvi S, Foca F, et al. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther. 2016;9:2735-42.	https://doi.org/10.2147/OTT.S105760						0				MIR17HG Amplification		MEL-IPI_Pat162	MEL-IPI_Pat162-Tumor-SM-7A15D	
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214												0				CDKN2A Deletion		MEL-IPI_Pat162	MEL-IPI_Pat162-Tumor-SM-7A15D	
Putatively Actionable	Preclinical			Copy Number	CDKN2B	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214												0				CDKN2B Deletion		MEL-IPI_Pat162	MEL-IPI_Pat162-Tumor-SM-7A15D	
Investigate Actionability - High		Clinical evidence	Clinical evidence	Somatic Variant	TP53	Missense	p.R175H	0.963	135.0	8e-06	0.0								Investigate Actionability - Low	Lenalidomide	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability - High	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				TP53 p.R175H (Missense)		MEL-IPI_Pat162	MEL-IPI_Pat162-Tumor-SM-7A15D	MEL-IPI_Pat162-Normal-SM-5VWIM
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																				Investigate Actionability - High	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat162		
Investigate Actionability - Low	Preclinical			Somatic Variant	AKT3	Splice Site	p.L233L	0.037000000000000005	243.0	0.0	0.0		Investigate Actionability - Low	MK-2206	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230												0				AKT3 p.L233L (Splice Site)	0.0	MEL-IPI_Pat162	MEL-IPI_Pat162-Tumor-SM-7A15D	MEL-IPI_Pat162-Normal-SM-5VWIM
Biologically Relevant				Copy Number	NF1	Deletion				0.0	0.0																			0				NF1 Deletion		MEL-IPI_Pat162	MEL-IPI_Pat162-Tumor-SM-7A15D	
Biologically Relevant				Copy Number	RET	Deletion				0.0	0.0																			0				RET Deletion		MEL-IPI_Pat162	MEL-IPI_Pat162-Tumor-SM-7A15D	
Biologically Relevant				Copy Number	EZH2	Deletion				0.0	0.0																			0				EZH2 Deletion		MEL-IPI_Pat162	MEL-IPI_Pat162-Tumor-SM-7A15D	
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.893																							0				COSMIC Signature 1 (89%)		MEL-IPI_Pat162		
